These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 7664265)
1. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Reichardt JK; Makridakis N; Henderson BE; Yu MC; Pike MC; Ross RK Cancer Res; 1995 Sep; 55(18):3973-5. PubMed ID: 7664265 [TBL] [Abstract][Full Text] [Related]
2. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Lunn RM; Bell DA; Mohler JL; Taylor JA Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617 [TBL] [Abstract][Full Text] [Related]
3. Prostatic steroid 5 alpha-reductase, an androgen metabolic gene. Reichardt JK Mayo Clin Proc; 2000 Jan; 75 Suppl():S36-9. PubMed ID: 10959214 [TBL] [Abstract][Full Text] [Related]
4. Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Devgan SA; Henderson BE; Yu MC; Shi CY; Pike MC; Ross RK; Reichardt JK Prostate; 1997 Sep; 33(1):9-12. PubMed ID: 9294620 [TBL] [Abstract][Full Text] [Related]
5. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Neslund-Dudas C; Bock CH; Monaghan K; Nock NL; Yang JJ; Rundle A; Tang D; Rybicki BA Prostate; 2007 Nov; 67(15):1654-63. PubMed ID: 17823934 [TBL] [Abstract][Full Text] [Related]
6. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Makridakis NM; Ross RK; Pike MC; Crocitto LE; Kolonel LN; Pearce CL; Henderson BE; Reichardt JK Lancet; 1999 Sep; 354(9183):975-8. PubMed ID: 10501358 [TBL] [Abstract][Full Text] [Related]
7. A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: a case-control analysis. Kantoff PW; Febbo PG; Giovannucci E; Krithivas K; Dahl DM; Chang G; Hennekens CH; Brown M; Stampfer MJ Cancer Epidemiol Biomarkers Prev; 1997 Mar; 6(3):189-92. PubMed ID: 9138662 [TBL] [Abstract][Full Text] [Related]
8. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Zeigler-Johnson CM; Walker AH; Mancke B; Spangler E; Jalloh M; McBride S; Deitz A; Malkowicz SB; Ofori-Adjei D; Gueye SM; Rebbeck TR Hum Hered; 2002; 54(1):13-21. PubMed ID: 12446983 [TBL] [Abstract][Full Text] [Related]
9. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572 [TBL] [Abstract][Full Text] [Related]
10. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Torkko KC; van Bokhoven A; Mai P; Beuten J; Balic I; Byers TE; Hokanson JE; Norris JM; Barón AE; Lucia MS; Thompson IM; Leach RJ Clin Cancer Res; 2008 May; 14(10):3223-9. PubMed ID: 18483391 [TBL] [Abstract][Full Text] [Related]
11. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Makridakis N; Ross RK; Pike MC; Chang L; Stanczyk FZ; Kolonel LN; Shi CY; Yu MC; Henderson BE; Reichardt JK Cancer Res; 1997 Mar; 57(6):1020-2. PubMed ID: 9067262 [TBL] [Abstract][Full Text] [Related]
12. No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned. Pearce CL; Van Den Berg DJ; Makridakis N; Reichardt JK; Ross RK; Pike MC; Kolonel LN; Henderson BE Hum Mol Genet; 2008 Aug; 17(16):2456-61. PubMed ID: 18469342 [TBL] [Abstract][Full Text] [Related]
13. GEN GEN: the genomic genetic analysis of androgen-metabolic genes and prostate cancer as a paradigm for the dissection of complex phenotypes. Reichardt JK Front Biosci; 1999 Jul; 4():D596-600. PubMed ID: 10417059 [TBL] [Abstract][Full Text] [Related]
14. Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5alpha-reductase during prostate cancer progression. Akalu A; Dlmajian DA; Highshaw RA; Nichols PW; Reichardt JK J Urol; 1999 Apr; 161(4):1355-8. PubMed ID: 10081907 [TBL] [Abstract][Full Text] [Related]
15. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134 [TBL] [Abstract][Full Text] [Related]
17. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men. Allen NE; Reichardt JK; Nguyen H; Key TJ Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):578-81. PubMed ID: 12815006 [TBL] [Abstract][Full Text] [Related]
18. The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population. Choi SY; Kim HJ; Cheong HS; Myung SC Korean J Urol; 2015 Jan; 56(1):19-30. PubMed ID: 25598933 [TBL] [Abstract][Full Text] [Related]
19. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Söderström T; Wadelius M; Andersson SO; Johansson JE; Johansson S; Granath F; Rane A Pharmacogenetics; 2002 Jun; 12(4):307-12. PubMed ID: 12042668 [TBL] [Abstract][Full Text] [Related]
20. Polymorphism of the SRD5A2 gene and the risk of prostate cancer. Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]